Investors with a short-term perspective can consider buying the stock of Natco Pharma at current levels. The stock encountered a key medium-term term resistance at around ₹1,050 in mid-January 2018 and began to decline. This down move was sharp and the stock breached the key supports at ₹900 and ₹800 levels while trending down. However, the stock found support at the significant medium-term base level of ₹700 last week.
Triggered by positive divergence in the daily relative strength index and price rate of change indicator, the stock changed direction. The stock has gained 9 per cent so far this week and has surpassed its 21-DMA resistance. Moreover, the stock has formed a bullish engulfing candlestick pattern in the weekly chart indicating a potential short-term trend reversal.
The daily and weekly RSI have entered the neutral region from the bearish zone. Though there is a key resistance at ₹800, the stock has bullish momentum to breach it and trend higher. The short-term targets are ₹815 and ₹830. Traders can buy the stock with a stop-loss at ₹770.
(Note: The recommendations are based on technical analysis. There is a risk of loss in trading.)
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.